USB Upgrades Esperion to 'Outperform'

Analyst Mark Schoenenbaum says the company's artery drug trial met its goals of cleansing coronary arteries

USB Bancorp upgraded Esperion Therapeutics (ESPR ) to outperform.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.